3.80

2.43% 0.09

After Hours: 3.56 -0.24 -6.32%

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is traded at $3.80, with a volume of 34,245. It is up +2.43% in the last 24 hours and up +9.20% over the past month. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Previous Close:

$3.71

Open:

$3.8119

24h Volume:

34,245

Relative Volume:

1.42

Market Cap:

$20.65M

Revenue:

Net Income/Loss:

$-14.29M

P/E Ratio:

-0.9524

EPS:

-3.99

Net Cash Flow:

$-12.27M

1W Performance:

-6.63%

1M Performance:

+9.20%

6M Performance:

-0.13%

1Y Performance:

-26.20%

1-Day Range:

$3.58

$3.985

1-Week Range:

$3.58

$4.50

52-Week Range:

$2.1501

$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

617-463-9385

Address

3805 OLD EASTON ROAD, DOYLESTOWN, MA

Employee

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

APRE's Discussions on Twitter

Compare APRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APRE Aprea Therapeutics Inc	3.80	20.65M	0	-14.29M	-12.27M	-3.99
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

Jan 21, 2025

Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail

Jan 21, 2025

APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat

Jan 21, 2025

Jan 20, 2025

Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World

Jan 20, 2025

StockNews.com Begins Coverage on SenesTech (NASDAQ:SNES) - Defense World

Jan 20, 2025

Jan 17, 2025

H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN

Jan 17, 2025

HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Jan 17, 2025

Jan 09, 2025

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MSN

Jan 09, 2025

Jan 07, 2025

Chronic Lymphocytic Leukemia Therapeutics Market Size in the 7MM is projected to grow during the forecast period 2024-2034 and estimated DelveInsight - The Globe and Mail

Jan 07, 2025

Jan 02, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times

Jan 02, 2025

Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan

Jan 02, 2025

Dec 30, 2024

Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Expands By 16.4% - Defense World

Dec 30, 2024

Dec 19, 2024

HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Dec 19, 2024

Dec 11, 2024

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times

Dec 11, 2024

Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan

Dec 11, 2024

Nov 22, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN

Nov 22, 2024

Nov 21, 2024

HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World

Nov 21, 2024

Nov 20, 2024

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024